-+ 0.00%
-+ 0.00%
-+ 0.00%

Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema

PUBT·08/25/2026 06:36:01
Listen to the news
Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema
  • Chugai filed for Japanese regulatory approval of vamikibart to treat uveitic macular edema linked to non-infectious uveitis.
  • Japan’s health ministry granted orphan drug designation for the indication on June 23, 2026.
  • Submission supported by global Phase 3 MEERKAT and SANDCAT trial results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.